Vemurafenib Drug Asset Due Diligence Report 2026

This Vemurafenib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

177

Registered trials

219

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Vemurafenib can convert its Small molecule drug profile and BRAF V600E biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Vemurafenib (query alias: vemurafenib)
Modality / target	Small molecule drug; BRAF V600E; BRAF V600E inhibitors
Highest global status	Approved
Originator	Daiichi Sankyo Co., Ltd.
Active developers	Hoffmann-La Roche, Inc., Roche Registration GmbH, Roche Pharma (Schweiz) AG

The MCP disease footprint includes BRAF mutation positive Melanoma, BRAF V600 mutation-positive Melanoma, Melanoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2500105081	Phase 4	Not yet recruiting	5	Objective Response Rate
CTR20253233	Not Applicable	进行中（招募中）	30	Not disclosed
CTR20260566	Not Applicable	进行中（尚未招募）	20	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Phase 2; n=24; evaluation: not stated. Reported fields: -; -; RR = 100 percentage of participants (95% Confidence Interval, 100 - 100)

Combination of vemurafenib with cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with nivolumab and ipilimumab (COWBOY): A randomized, open-label phase 2 clinical trial.

Phase 2; n=71; evaluation: Negative. Reported fields: BOR = In arm A, the BOR was partial response (PR) in 75% of the pts (36.1% had an ongoing response after treatment switch), stable disease (SD) in 22.2%, and progressive disease (PD) in 2.8%. In arm B, 54.3% had PR, 22.9% SD, and 20% PD (1 pt was not evaluable). ; BOR = In arm A, the BOR was partial response (PR) in 75% of the pts (36.1% had an ongoing response after treatment switch), stable disease (SD) in 22.2%, and progressive disease (PD) in 2.8%. In arm B, 54.3% had PR, 22.9% SD, and 20% PD (1 pt was not evaluable).

Linking T-cell receptor dynamics to outcomes in neoadjuvant-treated melanoma.

Phase 2; n=30; evaluation: Positive. Reported fields: DMFS = 64.3 % ( 48 - 86.3)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Vemurafenib addresses BRAF mutation positive Melanoma, BRAF V600 mutation-positive Melanoma, Melanoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-08-02	Roche and KeChow Reach a Cooperation Agreement	Approved	Financial terms not disclosed
2011-04-04	Daiichi Sankyo Completes Plexxikon Acquisition	Phase 3	US$805.0M upfront; US$130.0M milestones
2006-10-04	Plexxikon and Roche Enter Partnership to Develop Targeted Cancer Therapeutic Medicine PLX4032	Clinical	US$40.0M upfront; US$660.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO